Recent Label Changes and FDA Safety Signals
- ELOCON: Adds pediatric approval d...
- ZYRTEC ALLERGY: Withdrawal itching risk, ...
- FETROJA: Blood and lymphatic syste...
- FERAHEME: Irritation and long-lasti...
- OLUMIANT: Risk of severe hypoglycem...
- XELJANZ: In patients with diabetes...
- RINVOQ: In patients with diabetes...
- ANZUPGO: Treatment with oral
JAK ...
- LEQSELVI: Risk of low blood sugar (...
- LITFULO: Risk of low blood sugar (...
Poll
Subscribe to our free consumer-friendly health newsletter:
Medical research, new treatments, drug safety, health tips and more; delivered every other Sunday.
2026 New and Expanded Drug Approvals:
April 2026 New and Expanded Drug Approvals: For Weight Loss, Cystic Fibrosis (CF), Hunter Syndrome, Pain Pad, LAD-I, Hodgkin Lymphoma
March 2026 New and Expanded Drug Approvals: Newly approved treatments for common conditions like plaque psoriasis, obesity (the new High dose Wegovy), and liver conditions, as well as rare genetic conditions like achodroplasia.
Check out our new FDA Adverse Event Summaries:
Updated Leqembi treatment Adverse Event Monitoring System (AEMS) interactive dashboard. Covers through June 5, 2026.
Also check out our one-page
summary of AEMS reports covering older drugs like:
Amlodopine Besylate (Amlodopine is a
commonly-used calcium channel blocker drug used to treat high blood
pressure) as well as newer drugs like Cobenfy (xanomeline and trospium
chloride) for schizophrenia:
Cobenfy AEMS Reports Summary.
Recent Reviews
7/18/2026
Top 10 Treatment
Categories
